About US
Contact us
>>Back
Next up for HIV prevention testing: Viiv's Selzentry
- Publisher：
- Publication：2012/7/20
Truvada may have been the first HIV fighter to be approved for prevention, but it may not be the last. Already, the National Institutes of Health has announced a study for another drug, Selzentry.
Sold by the ViiV Healthcare joint venture between GlaxoSmithKline ($GSK) and Pfizer ($PFE), Selzentry will be tested in three drug combinations and compared with Truvada, made by Gilead Sciences ($GILD). Patients will be gay and bisexual men not infected with HIV. The aim of the study is to determine whether Selzentry is safe and well-tolerated by patients, and is a necessary precursor to testing for efficacy.
The Selzentry study is aimed at a couple of remaining concerns about preventive use of HIV drugs. FDA gave its blessing to Truvada as a prevention tool earlier this week, but critics said the approval could end up fostering drug-resistant strains of the virus. Plus, as The Wall Street Journal points out, the study investigators said they're also concerned about Truvada's safety risks.